Recent repurposing of the Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) system for transcriptional modulation has opened up new avenues of therapeutic opportunities at the transcription level, which had previously been considered an “undruggable” goal. Transcription-level control over genes involved in acute and chronic pain has the potential to generate a universal therapeutic modality to control pain without risking permanent changes in DNA or unintended side effects of small molecule treatment.
Description
Researchers have employed replication-deficient herpes simplex virus-1 to deliver CRISPR modulators to mouse models in order to examine the ameliorative effects on stimulus-induced pain. The goal is to develop effective, specific, and durable multiplex pain management therapy using CRISPR-HSV sensory nerve targeting technology.
Applications
· Treating acute and chronic pain
Advantages
· Novel method of using CRISPR technology with epigenetic modulation to achieve pain modulation
Invention Readiness
Design
IP Status
https://patents.google.com/patent/US20220325298A1
